[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.197.124.106. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Article
June 1992

Intralesional Cyclosporine for PsoriasisRelationship of Dose, Tissue Levels, and Efficacy

Author Affiliations

From the Dermatopharmacology Unit, Department of Dermatology (Drs Burns, Ellis, Eisen, Duell, Griffiths, and Voorhees and Mr Hamilton) and Department of Pathology (Dr Annesley), University of Michigan Medical Center, Ann Arbor; and Sandoz Research Institute, East Hanover, NJ (Dr Birnbaum).

Arch Dermatol. 1992;128(6):786-790. doi:10.1001/archderm.1992.01680160070006
Abstract

• Background and Design.—  To avoid systemic side effects, topical and intralesional administration of cyclosporine has been used; however, only intralesional administration has been successful. To understand more about the dosing requirements and resultant tissue levels of intralesional cyclosporine, we injected psoriasis plaques in a double-blind fashion with three different concentrations of cyclosporine (17 mg/mL in seven patients, 10 mg/mL in 13 patients, and 2.5 mg/mL in 11 patients) or matching vehicle three times weekly for 4 weeks.

Results.—  Statistically significant improvement was observed in plaques treated with 17 mg/mL (P =.003) compared with vehicle-treated plaques; the improvements in plaques treated with 10 mg/mL (P=.078) and 2.5 mg/mL (P=.054) achieved marginal statistical significance compared with vehicle treatment. Four weeks after discontinuation of ther

×